## Protocol Section
### Identification Module
**NCT ID:** NCT05398679

**Acronym:** OraPAT-IEGAMES

**Brief Title:** Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

**Official Title:** Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

#### Organization Study ID Info
**ID:** OraPAT-IE GAMES
#### Organization
**Class:** OTHER
**Full Name:** Fundacion Clinic per a la Recerca Biomédica
### Status Module
#### Completion Date
**Date:** 2024-12-30

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2022-06-01

**Type:** ACTUAL

**Last Update Submit Date:** 2022-05-26

**Overall Status:** NOT_YET_RECRUITING

#### Primary Completion Date
**Date:** 2024-06-30

**Type:** ESTIMATED

#### Start Date
**Date:** 2022-06-01

**Type:** ESTIMATED

**Status Verified Date:** 2022-05

#### Study First Post Date
**Date:** 2022-06-01
**Type:** ACTUAL
**Study First Submit Date:** 2022-05-04
**Study First Submit QC Date:** 2022-05-26
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** OTHER

**Name:** Fundacion Clinic per a la Recerca Biomédica

#### Responsible Party

**Investigator Affiliation:** Fundacion Clinic per a la Recerca Biomédica

**Investigator Full Name:** Anna Cruceta

**Investigator Title:** Project Manager Clinical Trial Unit

**Type:** PRINCIPAL_INVESTIGATOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** False

**Oversight Has DMC:** False

### Description Module

**Brief Summary:** Non-inferiority trial to determine whether partial oral treatment is non-inferior to OPAT(Outpatient parenteral therapy) in patients diagnosed with infective endocarditis

**Detailed Description:** The trial will include patients diagnosed with left-side Infective Endocarditis according to the modified Duke criteria, with ≥10 days of appropriate parenteral antibiotic treatment overall and at least one week of appropriate parenteral treatment after valve surgery

The patients will be randomized in two arms, one with oral antibiotic therapy and the other one with outpatient parenteral therapy

This trial aims to demonstrate the non-inferiority of outpatient oral antibiotic therapy in comparison with outpatient parenteral antibiotic treatment (OPAT), to improve the quality of life of infective endocarditis (IE) patients, and to reduce the cost of the intervention without increasing morbidity and mortality rates

### Conditions Module

**Conditions:**

- Endocarditis Infective

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

**Intervention Model Description:** National multi-center study, open, controlled, and randomized

##### Masking Info

**Masking:** NONE

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 360

**Type:** ESTIMATED

**Phases:**

- PHASE4

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Patients with infective endocarditis diagnostic, who have completed at least 10 days of intravenous therapy, and/ or seven days in the case of cardiac valvular surgery, and shown good clinical evolution and no clinical or echocardiographic signs of potential bad prognosis will be randomized. If assigned to this arm the patient will recieve parenteral antibiotics until the end of treatment.

**Intervention Names:**

- Drug: Cefaclor

- Drug: Ciprofloxacin Injection

- Drug: Clindamycin Injection

- Drug: Dicloxacillin

- Drug: Fusidic Acid Only Product in Parenteral Dose Form

- Drug: Levofloxacin Injection

- Drug: Linezolid Injectable Product

- Drug: Moxifloxacin Injectable Product

- Drug: Rifampicin Only Product in Parenteral Dose Form

- Drug: Sulfamethoxazole / Trimethoprim Injectable Product

- Drug: Tedizolid Injection

- Drug: Amoxicillin

**Label:** OPAT

**Type:** ACTIVE_COMPARATOR

#### Arm Group 2

**Description:** Patients with infective endocarditis diagnostic, who have completed at least 10 days of intravenous therapy, and/ or seven days in the case of cardiac valvular surgery, and shown good clinical evolution and no clinical or echocardiographic signs of potential bad prognosis will be randomized. If assigned to this arm the patient will recieve oral antibiotics until the end of treatment.

**Intervention Names:**

- Drug: Ciprofloxacin Tablets

- Drug: Clindamycin Oral Capsule

- Drug: Dicloxacillin Oral Capsule

- Drug: Fusidic Acid Only Product in Oral Dose Form

- Drug: Levofloxacin Oral Tablet

- Drug: Linezolid Oral Tablet

- Drug: Moxifloxacin tablet

- Drug: Rifampicin Only Product in Oral Dose Form

- Drug: Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]

- Drug: Tedizolid Oral Tablet

- Drug: Amoxicillin Capsules

- Drug: Cefaclor Capsules

**Label:** Oral Therapy

**Type:** EXPERIMENTAL

### Interventions

#### Intervention 1

**Arm Group Labels:**

- OPAT

**Description:** cefaclor intravenous 2 gr/day

**Name:** Cefaclor

**Type:** DRUG

#### Intervention 2

**Arm Group Labels:**

- Oral Therapy

**Description:** 500-750 mg/12 hrs (maximum 3g x day)

**Name:** Ciprofloxacin Tablets

**Type:** DRUG

#### Intervention 3

**Arm Group Labels:**

- OPAT

**Description:** 1200 mg/day maximum dose IV

**Name:** Ciprofloxacin Injection

**Type:** DRUG

#### Intervention 4

**Arm Group Labels:**

- Oral Therapy

**Description:** 600 mg/8 hours (maximum 1.800 mg x day)

**Name:** Clindamycin Oral Capsule

**Type:** DRUG

#### Intervention 5

**Arm Group Labels:**

- OPAT

**Description:** 600 mg/8 hours (maximum 1.800 mg x day) IV

**Name:** Clindamycin Injection

**Type:** DRUG

#### Intervention 6

**Arm Group Labels:**

- Oral Therapy

**Description:** 1g/8 hours (maximum 4 gr day)

**Name:** Dicloxacillin Oral Capsule

**Type:** DRUG

#### Intervention 7

**Arm Group Labels:**

- OPAT

**Description:** 1g/8 hours (maximum 4 g x day) IV

**Name:** Dicloxacillin

**Type:** DRUG

#### Intervention 8

**Arm Group Labels:**

- Oral Therapy

**Description:** 0,750g/12 hours (maximum 1,5 g x day)

**Name:** Fusidic Acid Only Product in Oral Dose Form

**Type:** DRUG

#### Intervention 9

**Arm Group Labels:**

- OPAT

**Description:** 0,75 g/12 hours (maximum 1,5 g x day)

**Name:** Fusidic Acid Only Product in Parenteral Dose Form

**Type:** DRUG

#### Intervention 10

**Arm Group Labels:**

- Oral Therapy

**Description:** 0.5g/12-24hours (maximum 1 g x day)

**Name:** Levofloxacin Oral Tablet

**Type:** DRUG

#### Intervention 11

**Arm Group Labels:**

- OPAT

**Description:** 0.5g/12-24hours (maximum 1 g x day)

**Name:** Levofloxacin Injection

**Type:** DRUG

#### Intervention 12

**Arm Group Labels:**

- Oral Therapy

**Description:** 0,6 g/12 hours (maximum 1200 mg x day)

**Name:** Linezolid Oral Tablet

**Type:** DRUG

#### Intervention 13

**Arm Group Labels:**

- OPAT

**Description:** 0,6 g/12 hours (maximum 1200 mg x day)

**Name:** Linezolid Injectable Product

**Type:** DRUG

#### Intervention 14

**Arm Group Labels:**

- Oral Therapy

**Description:** 0,4 g/day (maximum 400 mg x day)

**Name:** Moxifloxacin tablet

**Type:** DRUG

#### Intervention 15

**Arm Group Labels:**

- OPAT

**Description:** 0,4 g/day (maximum 400 mg x day)

**Name:** Moxifloxacin Injectable Product

**Type:** DRUG

#### Intervention 16

**Arm Group Labels:**

- Oral Therapy

**Description:** 0,3-0,5 g/12 hours (maximum 1200 mg x day)

**Name:** Rifampicin Only Product in Oral Dose Form

**Type:** DRUG

#### Intervention 17

**Arm Group Labels:**

- OPAT

**Description:** 0,3-0,6 g/12 hours (maximum 1200 mg x day)

**Name:** Rifampicin Only Product in Parenteral Dose Form

**Type:** DRUG

#### Intervention 18

**Arm Group Labels:**

- Oral Therapy

**Description:** sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)

**Name:** Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]

**Type:** DRUG

#### Intervention 19

**Arm Group Labels:**

- OPAT

**Description:** sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)

**Name:** Sulfamethoxazole / Trimethoprim Injectable Product

**Type:** DRUG

#### Intervention 20

**Arm Group Labels:**

- Oral Therapy

**Description:** 200 mg tedizolid (maximum x day)

**Name:** Tedizolid Oral Tablet

**Type:** DRUG

#### Intervention 21

**Arm Group Labels:**

- OPAT

**Description:** 200 mg (maximum x day)

**Name:** Tedizolid Injection

**Type:** DRUG

#### Intervention 22

**Arm Group Labels:**

- Oral Therapy

**Description:** 1 gr/6 hours (4 g x day)

**Name:** Amoxicillin Capsules

**Type:** DRUG

#### Intervention 23

**Arm Group Labels:**

- OPAT

**Description:** 1 gr/6 hours (4 g x day) Intravenous

**Name:** Amoxicillin

**Type:** DRUG

#### Intervention 24

**Arm Group Labels:**

- Oral Therapy

**Description:** 2 gr/day

**Name:** Cefaclor Capsules

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Measure:** Non-inferiority of outpatient oral vs parenteral antibiotic therapy measured by the number of unplanned hospitalizations

**Time Frame:** At any time during the study duration (up to 24 months)

**Measure:** Non-inferiority of outpatient oral vs parenteral antibiotic therapy measured by the number of all-cause mortality

**Time Frame:** At any time during the study duration (up to 24 months)

**Measure:** Non-inferiority of outpatient oral vs parenteral antibiotic therapy measured by the number of relapses of Infective Endocarditis

**Time Frame:** within 6 months from diagnosis of Infective Endocarditis

**Measure:** Non-inferiority of outpatient oral vs parenteral antibiotic therapy measured by the number of patients requiring cardiac surgery

**Time Frame:** At any time during the study duration (up to 24 months)

#### Secondary Outcomes

**Measure:** Quality of life and patient satisfaction of infective endocarditis patients. It will be measured through the standardized Saillen questionnaire of antibiotic treatment satisfaction

**Time Frame:** At any time during the study duration (up to 24 months)

**Description:** through a pharmacoeconomic analysis

**Measure:** Costs of both interventions, measured through a pharmaco-economic sub-study including direct and indirect costs, following the methodology described by Lacroix A et al Med Mal Infect. 2014

**Time Frame:** At any time during the study duration (up to 24 months)

**Description:** such as antibiotic or catheter-related adverse events e.g.,phlebitis and line-related bloodstream infections, and superinfections

**Measure:** The complications related to parenteral and oral administration of antibiotics will be measured through the number of antibiotic adverse reactions, catheter-related adverse events, and number of superinfections

**Time Frame:** At any time during the study duration (up to 24 months)

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Left-sided native or prosthetic infective endocarditis based on the modified Duke criteria infected with one of the following nonresistant microorganisms: Non-resistant streptococci and other gram positive cocci,e.g., Granulicatella and Abiotrophia; Enterococcus faecalis; Staphylococcus aureus;coagulase-negative staphylococci and HACEK group.
* Male or female 18 years old or older.
* 10 days or more of appropriate parenteral antibiotic treatment overall and at least one week of appropriate parenteral treatment after value surgery.
* Temperature inferior to 38ºC for more than two days. 5. C-reactive protein dropped to \<25% of peak value or \<20 mg/l, and white blood cell count \<15x10\^9/l during antibiotic treatment
* Transthoracic / transesophageal echocardiography performed within 48 hours of randomization

Exclusion Criteria:

* Body mass index \>40
* Concomitant infection requiring intravenous antibiotic therapy
* Inability to give informed consent to participation
* Suspicion of reduced absorption of oral treatment due to abdominal disorder
* Microorganisms with no oral combinations for treatment (two active antibiotics of different families)
* Any immunosuppressive disease or any medical condition at the discretion of the investigator that may preclude oral or OPAT therapy
* No family or appropriate home support
* Reduced compliance
* Women of childbearing potential with a positive pregnancy test, or participants (male or female) who wish to plan a pregnancy during the trial period
* Women in lactancy period

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** acruceta@clinic.cat

**Name:** Anna Cruceta

**Phone:** +34 932275400

**Phone Ext:** 4380

**Role:** CONTACT

**Contact 2:**

**Email:** burunat@clinic.cat

**Name:** Laura Burunat

**Phone:** +34 932275400

**Phone Ext:** 4198

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Barcelona

**Contacts:**

***Contact 1:***

- **Email:** acruceta@clinic.cat

- **Name:** Anna Cruceta, MD

- **Phone:** +34 932275400

- **Phone Ext:** 4380

- **Role:** CONTACT

***Contact 2:***

- **Email:** burunat@clinic.cat

- **Name:** Laura Burunat

- **Phone:** +34 932275400

- **Phone Ext:** 4198

- **Role:** CONTACT

***Contact 3:***

- **Name:** Juan Ambrosioni, MD

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** Spain

**Facility:** Hospital Clinic i Provincial de Barcelona

**Zip:** 08036

### IPD Sharing Statement Module

**IPD Sharing:** UNDECIDED

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000006331

- Term: Heart Diseases

- ID: D000002318

- Term: Cardiovascular Diseases

- ID: D000001424

- Term: Bacterial Infections

- ID: D000001423

- Term: Bacterial Infections and Mycoses

- ID: D000007239

- Term: Infections

- ID: D000053821

- Term: Cardiovascular Infections

### Condition Browse Module - Browse Branches

- Abbrev: BC01

- Name: Infections

- Abbrev: BC14

- Name: Heart and Blood Diseases

- Abbrev: All

- Name: All Conditions

- Abbrev: BC23

- Name: Symptoms and General Pathology

- Abbrev: Rare

- Name: Rare Diseases

### Condition Browse Module - Browse Leaves

- ID: M7859

- Name: Endocarditis, Bacterial

- Relevance: HIGH

- As Found: Infective Endocarditis

- ID: M7858

- Name: Endocarditis

- Relevance: HIGH

- As Found: Endocarditis

- ID: M9419

- Name: Heart Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M10283

- Name: Infections

- Relevance: LOW

- As Found: Unknown

- ID: M6368

- Name: Communicable Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M4722

- Name: Bacterial Infections

- Relevance: LOW

- As Found: Unknown

- ID: M12136

- Name: Mycoses

- Relevance: LOW

- As Found: Unknown

- ID: M4721

- Name: Bacterial Infections and Mycoses

- Relevance: LOW

- As Found: Unknown

- ID: M27489

- Name: Cardiovascular Infections

- Relevance: LOW

- As Found: Unknown

- ID: T3065

- Name: Infective Endocarditis

- Relevance: HIGH

- As Found: Infective Endocarditis

### Condition Browse Module - Meshes

- ID: D000004697

- Term: Endocarditis, Bacterial

- ID: D000004696

- Term: Endocarditis

### Intervention Browse Module - Ancestors

- ID: D000000900

- Term: Anti-Bacterial Agents

- ID: D000000890

- Term: Anti-Infective Agents

- ID: D000059005

- Term: Topoisomerase II Inhibitors

- ID: D000059003

- Term: Topoisomerase Inhibitors

- ID: D000004791

- Term: Enzyme Inhibitors

- ID: D000045504

- Term: Molecular Mechanisms of Pharmacological Action

- ID: D000000970

- Term: Antineoplastic Agents

- ID: D000080066

- Term: Contraceptive Agents, Hormonal

- ID: D000003270

- Term: Contraceptive Agents

- ID: D000012102

- Term: Reproductive Control Agents

- ID: D000045505

- Term: Physiological Effects of Drugs

- ID: D000003277

- Term: Contraceptives, Oral, Combined

- ID: D000003276

- Term: Contraceptives, Oral

- ID: D000003271

- Term: Contraceptive Agents, Female

- ID: D000000892

- Term: Anti-Infective Agents, Urinary

- ID: D000065609

- Term: Cytochrome P-450 CYP1A2 Inhibitors

- ID: D000065607

- Term: Cytochrome P-450 Enzyme Inhibitors

- ID: D000000904

- Term: Antibiotics, Antitubercular

- ID: D000000995

- Term: Antitubercular Agents

- ID: D000007917

- Term: Leprostatic Agents

- ID: D000019384

- Term: Nucleic Acid Synthesis Inhibitors

- ID: D000065695

- Term: Cytochrome P-450 CYP2B6 Inducers

- ID: D000065693

- Term: Cytochrome P-450 Enzyme Inducers

- ID: D000065696

- Term: Cytochrome P-450 CYP2C8 Inducers

- ID: D000065697

- Term: Cytochrome P-450 CYP2C19 Inducers

- ID: D000065698

- Term: Cytochrome P-450 CYP2C9 Inducers

- ID: D000065701

- Term: Cytochrome P-450 CYP3A Inducers

- ID: D000011500

- Term: Protein Synthesis Inhibitors

- ID: D000000962

- Term: Antimalarials

- ID: D000000981

- Term: Antiprotozoal Agents

- ID: D000000977

- Term: Antiparasitic Agents

- ID: D000005493

- Term: Folic Acid Antagonists

- ID: D000018726

- Term: Anti-Dyskinesia Agents

- ID: D000065687

- Term: Cytochrome P-450 CYP2C8 Inhibitors

### Intervention Browse Module - Browse Branches

- Abbrev: Infe

- Name: Anti-Infective Agents

- Abbrev: All

- Name: All Drugs and Chemicals

- Abbrev: ANeo

- Name: Antineoplastic Agents

- Abbrev: AnDyAg

- Name: Anti-Dyskinesia Agents

- Abbrev: Repr

- Name: Reproductive Control Agents

- Abbrev: Micro

- Name: Micronutrients

- Abbrev: Hemat

- Name: Hematinics

- Abbrev: Vi

- Name: Vitamins

### Intervention Browse Module - Browse Leaves

- ID: M3995

- Name: Amoxicillin

- Relevance: HIGH

- As Found: Pembrolizumab

- ID: M6176

- Name: Ciprofloxacin

- Relevance: HIGH

- As Found: Endothelial

- ID: M4222

- Name: Anti-Bacterial Agents

- Relevance: LOW

- As Found: Unknown

- ID: M6214

- Name: Clindamycin

- Relevance: HIGH

- As Found: Six months

- ID: M220697

- Name: Clindamycin palmitate

- Relevance: HIGH

- As Found: Six months

- ID: M231711

- Name: Clindamycin phosphate

- Relevance: HIGH

- As Found: Six months

- ID: M4214

- Name: Anti-Infective Agents

- Relevance: LOW

- As Found: Unknown

- ID: M30370

- Name: Levofloxacin

- Relevance: HIGH

- As Found: Sodium chloride

- ID: M17946

- Name: Ofloxacin

- Relevance: HIGH

- As Found: Sodium chloride

- ID: M1722

- Name: Moxifloxacin

- Relevance: HIGH

- As Found: Range

- ID: M5683

- Name: Cefaclor

- Relevance: HIGH

- As Found: Phase II/III Trial

- ID: M4224

- Name: Antibiotics, Antitubercular

- Relevance: LOW

- As Found: Unknown

- ID: M15118

- Name: Rifampin

- Relevance: HIGH

- As Found: Intrathecal

- ID: M400

- Name: Linezolid

- Relevance: HIGH

- As Found: Silicone

- ID: M18253

- Name: Trimethoprim, Sulfamethoxazole Drug Combination

- Relevance: HIGH

- As Found: Bone Tumors

- ID: M17047

- Name: Trimethoprim

- Relevance: HIGH

- As Found: Decision aid

- ID: M16206

- Name: Sulfamethoxazole

- Relevance: HIGH

- As Found: Epidermal

- ID: M266292

- Name: Norgestimate, ethinyl estradiol drug combination

- Relevance: HIGH

- As Found: Range

- ID: M8791

- Name: Fusidic Acid

- Relevance: HIGH

- As Found: Epistaxis

- ID: M7198

- Name: Dicloxacillin

- Relevance: HIGH

- As Found: Electronic monitoring

- ID: M266543

- Name: Tedizolid

- Relevance: HIGH

- As Found: PONV

- ID: M22872

- Name: Oxazolidinones

- Relevance: HIGH

- As Found: PONV

- ID: M8145

- Name: Ethinyl Estradiol

- Relevance: LOW

- As Found: Unknown

- ID: M266279

- Name: Estradiol 17 beta-cypionate

- Relevance: LOW

- As Found: Unknown

- ID: M266280

- Name: Estradiol 3-benzoate

- Relevance: LOW

- As Found: Unknown

- ID: M8108

- Name: Estradiol

- Relevance: LOW

- As Found: Unknown

- ID: M234941

- Name: Polyestradiol phosphate

- Relevance: LOW

- As Found: Unknown

- ID: M230936

- Name: Norgestimate

- Relevance: LOW

- As Found: Unknown

- ID: M7951

- Name: Enzyme Inhibitors

- Relevance: LOW

- As Found: Unknown

- ID: M6494

- Name: Contraceptive Agents

- Relevance: LOW

- As Found: Unknown

- ID: M2116

- Name: Contraceptive Agents, Hormonal

- Relevance: LOW

- As Found: Unknown

- ID: M6500

- Name: Contraceptives, Oral

- Relevance: LOW

- As Found: Unknown

- ID: M6501

- Name: Contraceptives, Oral, Combined

- Relevance: LOW

- As Found: Unknown

- ID: M6495

- Name: Contraceptive Agents, Female

- Relevance: LOW

- As Found: Unknown

- ID: M30537

- Name: Cytochrome P-450 Enzyme Inhibitors

- Relevance: LOW

- As Found: Unknown

- ID: M4311

- Name: Antitubercular Agents

- Relevance: LOW

- As Found: Unknown

- ID: M4280

- Name: Antimalarials

- Relevance: LOW

- As Found: Unknown

- ID: M4298

- Name: Antiprotozoal Agents

- Relevance: LOW

- As Found: Unknown

- ID: M4294

- Name: Antiparasitic Agents

- Relevance: LOW

- As Found: Unknown

- ID: M8618

- Name: Folic Acid

- Relevance: LOW

- As Found: Unknown

- ID: M17546

- Name: Vitamin B Complex

- Relevance: LOW

- As Found: Unknown

- ID: M8619

- Name: Folic Acid Antagonists

- Relevance: LOW

- As Found: Unknown

- ID: T447

- Name: Folinic Acid

- Relevance: LOW

- As Found: Unknown

- ID: T446

- Name: Folic Acid

- Relevance: LOW

- As Found: Unknown

- ID: T448

- Name: Folate

- Relevance: LOW

- As Found: Unknown

- ID: T475

- Name: Vitamin B9

- Relevance: LOW

- As Found: Unknown

### Intervention Browse Module - Meshes

- ID: D000000658

- Term: Amoxicillin

- ID: D000077266

- Term: Moxifloxacin

- ID: D000064704

- Term: Levofloxacin

- ID: D000015242

- Term: Ofloxacin

- ID: D000002939

- Term: Ciprofloxacin

- ID: D000012293

- Term: Rifampin

- ID: D000002981

- Term: Clindamycin

- ID: C000000489

- Term: Clindamycin palmitate

- ID: C000007084

- Term: Clindamycin phosphate

- ID: D000069349

- Term: Linezolid

- ID: D000015662

- Term: Trimethoprim, Sulfamethoxazole Drug Combination

- ID: C000546016

- Term: Tedizolid

- ID: D000005672

- Term: Fusidic Acid

- ID: D000004009

- Term: Dicloxacillin

- ID: D000002433

- Term: Cefaclor

- ID: D000014295

- Term: Trimethoprim

- ID: D000013420

- Term: Sulfamethoxazole

- ID: D000023303

- Term: Oxazolidinones

- ID: C000109079

- Term: Norgestimate, ethinyl estradiol drug combination

### Misc Info Module

- Version Holder: 2024-05-24
